Doctors Warn of Health Risks as Millions Start and Stop Ozempic and Other GLP-1 Weight Loss Drugs

TORONTO, CANADA: The growing popularity of GLP-1 weight loss medications is creating a new challenge for medical researchers as increasing numbers of people begin taking the drugs for rapid weight reduction before discontinuing treatment, raising concerns about weight regain, metabolic health and the potential consequences of repeated short-term use.

Medications such as Ozempic, Wegovy and Mounjaro have transformed the treatment of obesity and Type 2 diabetes, helping millions of patients control their appetite, manage blood sugar levels and achieve substantial weight loss. However, doctors are increasingly concerned that these powerful medications are being used for cosmetic purposes and temporary weight management rather than as treatments for chronic medical conditions.

Researchers in Canada and the United States are now investigating what happens when patients stop taking GLP-1 medications, whether gradually reducing the dosage offers advantages over stopping abruptly and whether repeated cycles of treatment could reduce their effectiveness.

The questions have become particularly important as social media trends, celebrity endorsements and growing online access encourage people to experiment with weight loss drugs without always understanding the long-term medical implications.

For many patients, the medications have produced life-changing results. Yet the decision to discontinue treatment can create uncertainty about whether those improvements will last.

One Canadian woman confronting that question is 32-year-old Beverley Smith of Halifax, Nova Scotia, who has been using tirzepatide while preparing for her wedding next summer.

Smith has experienced weight-related health challenges associated with polyendocrine metabolic ovarian syndrome and previously tried different medications to manage her symptoms.

Since beginning tirzepatide treatment in March, she has lost more than 30 pounds and reported improvements in symptoms including joint pain.

Although the treatment has significantly improved her health and quality of life, she remains uncertain about what will happen when she eventually decides to stop taking the medication.

Her concerns reflect those of many patients who have achieved successful weight loss but are unsure whether the results can be maintained without continued pharmaceutical treatment.

How GLP-1 Medications Work

GLP-1 medications work by imitating the activity of glucagon-like peptide-1, a naturally occurring hormone released by the body after eating.

The hormone helps regulate blood sugar, influences appetite and slows the movement of food through the stomach, contributing to a longer-lasting feeling of fullness.

These effects can reduce food consumption and support weight loss, particularly among patients living with obesity or Type 2 diabetes.

Some newer medications, including tirzepatide, act on more than one hormone pathway to improve metabolic regulation.

Although GLP-1 medications have become widely recognised only in recent years, the drug class has existed for more than two decades.

Earlier treatments were developed primarily for diabetes management before researchers demonstrated their effectiveness in supporting substantial weight reduction.

The medications have since become an important component of modern obesity treatment, with clinical research identifying benefits extending beyond weight loss in certain patient populations.

Studies have shown that some GLP-1 therapies can reduce cardiovascular risks, improve blood sugar control and help manage complications associated with obesity.

Researchers are also examining their potential effects on sleep apnea, substance use disorders and other medical conditions.

However, scientists emphasise that the strongest evidence comes from clinical trials involving patients with specific medical conditions and treatment plans.

The risks and benefits of using these medications temporarily for cosmetic weight loss remain far less understood.

Short-Term Weight Loss Trends Raise Concerns

Medical professionals have observed a growing number of people using GLP-1 medications for relatively short periods, often with the intention of losing weight before a wedding, vacation or another important event.

Some individuals have also begun experimenting with microdosing, intermittent treatment schedules or switching between different medications.

These practices have attracted attention on social media, where personal experiences and weight loss transformations are frequently presented without sufficient discussion of medical risks.

The increasing availability of online pharmacies and new oral formulations has also made these treatments more accessible in some markets.

However, easier access does not necessarily mean that every method of using the medications has been scientifically evaluated.

Dr. Thomas Leung, a clinician-scientist at the University of Pennsylvania, has been studying the potential consequences of repeatedly starting and stopping GLP-1 treatment.

Leung became interested in the issue after observing that some people wanted to use the medications for a few weeks or months before discontinuing them as quickly as possible.

While clinical trials have established the benefits of sustained treatment for eligible patients, comparatively little research has examined repeated cycles of medication use and withdrawal.

This gap in scientific knowledge prompted Leung and his colleagues to investigate the effects in laboratory animals.

Animal Research Suggests Repeated Use May Reduce Effectiveness

In a study involving overweight mice, Leung’s research team compared continuous GLP-1 treatment with a schedule in which medication was repeatedly started and stopped.

The animals receiving intermittent treatment were cycled on and off the drugs every two weeks.

Researchers found that the mice undergoing repeated treatment interruptions experienced less successful weight reduction than those receiving medication continuously.

Even after two months of consistent treatment at the end of the experiment, the group previously subjected to repeated interruptions remained approximately 20 per cent heavier than the continuously treated animals.

The findings raise questions about whether inconsistent treatment could influence the body’s response to GLP-1 medications over time.

However, the results come from animal research and cannot automatically be applied to human patients.

Human metabolism, medication responses and patterns of weight regain are more complex, and additional clinical studies are necessary to determine whether similar effects occur in people.

Nevertheless, the research provides an important reason to investigate the consequences of repeated short-term use.

Doctors are particularly interested in whether cycling between treatment and discontinuation could undermine weight management efforts or contribute to undesirable changes in metabolic health.

Weight Regain Could Reverse Important Health Benefits

One of the biggest concerns surrounding GLP-1 discontinuation is the possibility that patients will regain weight after stopping treatment.

Dr. Sean Wharton, an obesity medicine specialist associated with the Wharton Medical Clinic in Burlington, Ontario, has observed increasing interest in using the medications outside their established medical indications.

He warns that patients experimenting with unproven treatment schedules may be exposing themselves to risks that researchers have not yet fully identified.

Wharton emphasises that GLP-1 medications have demonstrated substantial benefits for patients with obesity, particularly because excess body weight can contribute to cardiovascular disease, inflammation and other serious medical conditions.

However, those benefits may diminish when treatment is discontinued and weight returns.

For example, patients whose blood pressure improves following significant weight loss may experience rising blood pressure again if they regain much of the weight.

Similar concerns apply to other metabolic improvements linked to sustained weight reduction.

Research reviews have identified weight regain and deterioration in certain cardiometabolic measurements following discontinuation of GLP-1 treatment.

The findings suggest that stopping medication may reverse some of the progress achieved during treatment, although individual outcomes vary.

This does not mean every patient will regain all the weight lost or experience the same health consequences.

Rather, doctors say the possibility of weight regain should be discussed before treatment begins, particularly when patients are considering using these medications for only a short period.

Canadian Researchers Investigate How to Stop Treatment Safely

Scientists in Toronto are now conducting a clinical trial to determine whether gradually reducing GLP-1 medication offers advantages over stopping treatment immediately.

The research involves Dr. Daniel Drucker, a prominent scientist whose work has contributed significantly to understanding GLP-1 biology, alongside endocrinologist Dr. Caroline Kramer and Dr. Sean Wharton.

Based at Mount Sinai Hospital, the study is designed to examine the effects of different approaches to discontinuing treatment.

Participants will be monitored during a 16-week research period, with investigators using blood tests and other clinical measurements to assess changes in their health.

The researchers aim to determine whether tapering medication can help preserve weight loss and metabolic improvements compared with abruptly stopping.

They will also monitor participants for symptoms and adverse events.

The investigation addresses an important gap in current medical knowledge because most major clinical trials have focused on starting treatment, increasing dosages and measuring the benefits of continued medication.

Far less attention has been devoted to identifying the safest and most effective methods of discontinuation.

Drucker believes this question deserves greater scientific attention, particularly as more patients begin using GLP-1 medications for reasons beyond traditional chronic disease management.

He has also challenged the perception that patients should necessarily be able to maintain medication-assisted weight loss without continued treatment.

Many chronic conditions require long-term medication, including high blood pressure, elevated cholesterol and several inflammatory diseases.

Obesity is similarly recognised as a chronic medical condition, and some patients may require ongoing treatment to maintain improvements.

Researchers hope the Toronto study will provide evidence to guide future medical recommendations and help patients make informed decisions about their treatment.

Side Effects Remain an Important Consideration

Although GLP-1 medications have demonstrated substantial benefits in appropriately selected patients, they can also cause side effects.

Common problems include nausea, vomiting, diarrhea, constipation and abdominal discomfort, particularly when treatment begins or doses are increased.

Some patients may experience more serious complications, including pancreatitis, gallbladder problems or severe gastrointestinal symptoms.

Rare reports of certain vision-related complications have also prompted further scientific investigation.

The risks vary depending on the specific medication, the patient’s medical history and other individual factors.

Doctors therefore recommend appropriate medical assessment and monitoring rather than experimenting independently with dosage changes or treatment interruptions.

Patients considering discontinuation should discuss their circumstances with a qualified healthcare professional, especially if the medication is being used to manage diabetes or another chronic condition.

Stopping diabetes treatment without an appropriate alternative plan can result in worsening blood sugar control.

Similarly, restarting a medication after a significant interruption may require medical guidance because tolerability and dosing needs can change.

The growing market for weight loss drugs has also created concerns about counterfeit and unauthorised products, making regulated sources and professional oversight especially important.

Experts Question the Rise of Cosmetic Weight Loss Treatments

The increasing use of GLP-1 medications for appearance-related goals has introduced new ethical and medical questions.

Unlike patients receiving treatment for obesity or diabetes, some individuals seeking short-term cosmetic weight loss may not have medical conditions for which the drugs have been adequately studied.

This creates uncertainty about the balance between potential benefits and adverse effects.

Dr. Caroline Kramer has warned that using these medications for short periods without a clear medical indication could, in some circumstances, create more harm than benefit.

Researchers remain particularly concerned about whether the cardiovascular improvements associated with treatment can be maintained after discontinuation.

They also want to understand how repeated weight loss and regain may affect long-term health.

The popularity of GLP-1 medications has moved faster than scientific understanding of every possible pattern of use.

While the medications have transformed obesity care, experts caution against assuming that approaches promoted through social media are necessarily safe or effective.

Long-Term Research Will Shape the Future of Weight Loss Treatment

The rapid expansion of GLP-1 treatment represents one of the most significant developments in modern metabolic medicine.

For patients living with obesity and Type 2 diabetes, these medications have created opportunities to improve health outcomes that were previously difficult to achieve through existing treatments alone.

However, their growing use for temporary weight reduction has introduced questions that medical researchers are only beginning to answer.

The evidence currently available supports their effectiveness for specific conditions when used according to established treatment guidelines.

What remains uncertain is whether repeated short-term treatment, microdosing or frequent interruptions can deliver comparable benefits without creating additional risks.

Researchers in Canada and the United States are working to close those knowledge gaps through clinical trials and laboratory investigations.

Their findings could eventually influence prescribing guidelines, discontinuation strategies and the way healthcare professionals counsel patients considering GLP-1 treatment.

For individuals such as Beverley Smith, who have experienced meaningful improvements in their health, the answers could help determine whether treatment must continue indefinitely or whether a carefully supervised withdrawal plan can preserve some of the benefits.

The broader message from medical experts is that GLP-1 medications should not be treated as ordinary short-term dieting products.

They are powerful prescription therapies that influence appetite, blood sugar regulation and other important physiological processes.

As their popularity continues to grow, the challenge for healthcare systems will be ensuring that access to these treatments is accompanied by reliable information, appropriate medical supervision and evidence-based decisions.

Until more research is available, patients considering starting, stopping or restarting GLP-1 medication should seek individual medical guidance rather than relying on untested weight loss trends.

The future of these medications may extend far beyond weight management, but understanding how to use them safely over time will be just as important as understanding how effectively they help people lose weight.

Courtesy: CBC